Retatrutide is the peptide LY3437943, a triple hormone receptor agonist that acts on three natural hormones that affect hunger. Like semaglutide (branded as Ozempic and Wegovy) that acts on one hunger hormone and tirzepatide (branded as Mounjaro and Zepbound) that acts on two hunger hormones, Retatrutide acts on three hormones: GIP, glucagon-like peptide-1 (GLP-1) and glucagon receptors just like the natural GLP-1 hormone in your body. This hormone regulates blood sugar and reduces appetite. By increasing the effect of this natural hormone, Retatrutide can improve glycemic control and help with feeling full and eating less. Retatrutide will be a once weekly injection.
Retatrutide is currently undergoing its phase 3 clinical trial, which involves mass testing the drug on several hundred patients. However, phase 3 is scheduled to continue until 2025, meaning the medication will not be available until at least 2026, provided the drug passes this last stage in the clinical trials.
The New England Journal of Medicine shows in the phase 2 clinical trials that Retatrutide achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity and overweight. Also, in a secondary endpoint, retatrutide demonstrated a mean weight reduction up to 24.2% at 48 weeks.Retatrutide is an injection that is administered once-weekly.
